The American Academy of Ophthalmology (AAO) 2026 Annual Meeting took place from October 9-12, 2026, in New Orleans, Louisiana. Bringing together retina specialists, ophthalmic and orbital surgeons, clinical investigators, and industry leaders, the meeting combined late-breaking Phase III readouts with expert debates and case-based panels spanning retinal disease and the wider ophthalmology landscape.

Key Themes and Highlights:

• Growing debate over structural versus functional benefit

  • In GA, complement inhibitors slowed lesion growth without measurable vision gains, while photobiomodulation and the Prima photovoltaic implant reported visual improvements.

• Shift from chronic disease management toward durable, mechanism-targeted, and potentially one-time treatment

  • Sustained-delivery platforms and gene therapies in wet AMD aim to reduce reliance on frequent bolus anti-VEGF injections, while gene augmentation and mutation-agnostic approaches in inherited retinal diseases advanced into pivotal trials and regulatory filings.

• Renewed momentum for vision restoration

  • The AAO followed shortly after the 2026 Nobel Prize in Physiology or Medicine was awarded for optogenetics with programs targeting vision restoration.

• Trial design and comparator performance shaping Phase III outcomes

  • Wet AMD results were mixed, from positive tarcocimab and OTX-TKI data to a missed non-inferiority endpoint for Duravyu.

• A market shifting toward premium branded agents, with gradual biosimilar uptake

  • Highlighted by Medicare Part B anti-VEGF spending trends.

These themes set the stage for this rapid readout, where we highlight key presentations and what they imply for near-term clinical development, regulatory strategy, and commercial positioning. Datamonitor analysts attended the meeting and have distilled the key signals and takeaways from the discussions on the ground.

For the full report, please download the PDF version at the top of this page .